Large prospective studies of cytarabine intensification for first-line MCL
| Regimen . | Reference (year) . | N . | ORR, % . | CRR, % . | Toxicity grade III-IV . |
|---|---|---|---|---|---|
| Hyper-CVAD/MTX-Ara-C | Khouri et al50 (1998) | 45 (20 untreated) | 93 | 38 | Thrombocytopenia 85%, infections 10% |
| Hyper-CVAD/MTX-Ara-C | Romaguera et al58 (2000) | 25 (age > 65 y) | 92 | 68 | Toxic death 8%, infections 5% |
| R-Hyper-CVAD/R-MTX-Ara-C | Romaguera et al52 (2005) | 97 | 97 | 87 | Toxic death 5%, MDS 3% |
| R-Hyper-CVAD/R-MTX-Ara-C | Epner et al53 (2007) | 49 | 88 | 58 | Toxic death 2%, hematotoxicity 87% |
| R-Hyper-CVAD/R-MTX-Ara-C | Merli et al54 (2008) | 32 | 53 | 50 | Toxic death 6%, severe infections 15% |
| R-DHAP | de Guibert et al57 (2006) | 25 | 96 | 92 | Thrombocytopenia 33% |
| CHOP × 3 + DHAP × 3 | Lefrère et al51 (2004) | 28 | 92 | 84 | — |
| R-CHOP × 3 + R-DHAP × 3 | Delarue et al55 (2008) | 60 | 95 | 61 | — |
| R-CHOP × 3 + HD-Ara-C × 1 | van't Veer et al56 (2008) | 87 | 72 | 29 | Infections 30% |
| Regimen . | Reference (year) . | N . | ORR, % . | CRR, % . | Toxicity grade III-IV . |
|---|---|---|---|---|---|
| Hyper-CVAD/MTX-Ara-C | Khouri et al50 (1998) | 45 (20 untreated) | 93 | 38 | Thrombocytopenia 85%, infections 10% |
| Hyper-CVAD/MTX-Ara-C | Romaguera et al58 (2000) | 25 (age > 65 y) | 92 | 68 | Toxic death 8%, infections 5% |
| R-Hyper-CVAD/R-MTX-Ara-C | Romaguera et al52 (2005) | 97 | 97 | 87 | Toxic death 5%, MDS 3% |
| R-Hyper-CVAD/R-MTX-Ara-C | Epner et al53 (2007) | 49 | 88 | 58 | Toxic death 2%, hematotoxicity 87% |
| R-Hyper-CVAD/R-MTX-Ara-C | Merli et al54 (2008) | 32 | 53 | 50 | Toxic death 6%, severe infections 15% |
| R-DHAP | de Guibert et al57 (2006) | 25 | 96 | 92 | Thrombocytopenia 33% |
| CHOP × 3 + DHAP × 3 | Lefrère et al51 (2004) | 28 | 92 | 84 | — |
| R-CHOP × 3 + R-DHAP × 3 | Delarue et al55 (2008) | 60 | 95 | 61 | — |
| R-CHOP × 3 + HD-Ara-C × 1 | van't Veer et al56 (2008) | 87 | 72 | 29 | Infections 30% |